Day: April 27, 2020

Kalamazoo, Michigan , April 27, 2020 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK) announced today that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI). The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical.The tender offer is now scheduled to expire at 5:00 p.m., Eastern Time, on June 30, 2020, unless the tender offer is further extended or earlier terminated in accordance with the purchase agreement.American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Stryker B.V. that as of 5:00 p.m., Eastern Time, on April 24, 2020, the last business...

ROCHESTER, N.Y., April 27, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced the presentation of updated interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor avelumab (BAVENCIO®) in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, being held April 27-28, 2020. The data will be presented in a virtual poster session, available on demand and free to anyone on the AACR website beginning April 27.The CLASSICAL-Lung trial (NCT03268057) is being conducted in collaboration with Merck KGaA, Darmstadt,...

STRONG GROWTH, DESPITE CORONA EFFECTSerstech Group – First Quarter 2020Net sales: KSEK 6 012 (3 251)Profit for the period: KSEK -3 206 (-3 660)Earnings per share SEK -0,04 (0,06)Earnings per average number of shares: SEK -0,04 (0,06)Several of the tenders that we expected to close in Q4 2019 resulted in orders during the first quarter of this year. Net sales increased by approximately 85%, despite the slowdown in March. We also saw a large inflow of new opportunities during the quarter and our sales pipeline increased by several million SEK every week until early March, resulting in the strongest pipeline in the history of the company. Before the downturn, the sum of the tenders our partners participated in was above 120 MSEK for the full year, which can be compared to just above 10 MSEK at the same time in 2019. This number has...

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.The following transactions have been executed during the period 20 – 24 April 2020:An overview showing the transaction data for the period  20 – 24 April 2020...

Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. Programmet begyndte den 24. februar 2020 og forventes afsluttet den 24. august 2020.Aktietilbagekøbsprogrammet struktureres i henhold til bestemmelserne i artikel 5 i EU-Parlamentet og Rådets forordning nr. 596/2014 af 16. april 2014 (MAR) og forordning 2016/1052, også kaldet ”Safe Harbour” reglerne, med det formål at opfylde forpligtelser i henhold til aktieoptionsprogrammer eller andre aktieallokeringer til medarbejdere eller at gennemføre en kapitalnedsættelse i henhold til artikel 5(2)(a) og artikel 5(2)(c) i MAR.            I perioden 20. – 24. april 2020 er der foretaget følgende køb:Coloplast ejer herefter  3.288.667 egne B-aktier à DKK 1 svarende til 1,52% af selskabets samlede aktiekapital.Separat oversigt...

BEIJING, China, April 27, 2020 (GLOBE NEWSWIRE) — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the Securities and Exchange Commission on April 27, 2020. The annual report can be accessed on the Company’s investor relations website at http://ir.soyoung.com/.The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, So-Young International Inc., Tower E, Ronsin Technology Center,...

ALAMEDA, Calif., April 27, 2020 (GLOBE NEWSWIRE) — DASAN Zhone Solutions, Inc. (NASDAQ: DZSI or the “Company” or “DZS”), a leading enabler of the emerging hyper-connected, hyper-broadband world, will hold a conference call on Thursday, May 7, 2020 at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2020. Financial results will be issued in a press release prior to the call.DZS management will host the conference call, followed by a question and answer period.Date: Thursday, May 7, 2020Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)U.S. dial-in number: 877-742-9182International number: 602-563-8857Conference ID: 1668748Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any...

Continue to address the impact of the COVID-19 pandemic on AMG’s Affiliates, business, employees, and surrounding communities — including supporting the relief efforts of local healthcare systemsOngoing execution of long-term growth strategy during the quarter: completed partnership with Comvest Capital Partners and announced strategic relationship with iCapitalCapitalized on balance sheet strength and flexibility: repurchased $70 million in common stock in Q1 and plan to reallocate $50 million of capital toward share repurchases, in lieu of dividend payments, over the balance of 2020      WEST PALM BEACH, Fla., April 27, 2020 (GLOBE NEWSWIRE) — Affiliated Managers Group, Inc. (NYSE: AMG) today reported its financial and operating results for the first quarter of 2020.Jay C. Horgen, President and Chief Executive Officer of...

Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival             Libtayo decreased the risk of death by 32.4% compared to chemotherapySanofi and Regeneron plan regulatory submissions in 2020Paris and Tarrytown, N.Y. – April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab) to platinum doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) that tested positive for PD-L1 in ≥50% of tumor cells. Based on a recommendation by the independent Data Monitoring Committee to stop the trial early, the trial...